Addendum: Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase ( MTAP ) loss

Maroun Bou Zerdan; Prashanth Ashok Kumar; Elio Haroun; Nimisha Srivastava; Jeffrey Ross; Abirami Sivapiragasam

doi:10.18632/oncotarget.28481

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss

PDF | How to cite

Oncotarget. 2023; 14:747-747. https://doi.org/10.18632/oncotarget.28481

Metrics: PDF 625 views | ?

Maroun Bou Zerdan¹, Prashanth Ashok Kumar², Elio Haroun³, Nimisha Srivastava², Jeffrey Ross^4,5 and Abirami Sivapiragasam²

¹Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA
²Department of Internal Medicine, Division of Hematology Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA
³SUNY Upstate Medical University, Syracuse, NY 13210, USA
⁴Foundation Medicine, Inc., Morrisville, NC 27560, USA
⁵Departments of Pathology and Urology, SUNY Upstate Medical University, Syracuse, NY 13210, USA

Published: August 7, 2023

Copyright: © 2023 Bou Zerdan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: No external funding was provided for this research.

Original article: Oncotarget. 2023; 14:178-187. DOI: https://doi.org/10.18632/oncotarget.28376.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28481

Publication Alerts

Post-Publication Promotion

Publication Discount

Addendum:

Addendum: Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss